INTRODUCTION
Epstein-Barr virus (EBV) is a ubiquitous γ-1 herpes virus usually acquired during childhood via salivary transmission, which establishes a life-long persistent infection of B cells in over 90% T lymphomas, NK cell malignancies, nasopharyngeal undifferentiated carcinomas and a subset of smooth muscle tumors. 2 EBV-associated gastric carcinoma (EBVaGC) is defined by the presence of EBV in gastric tumor cells by EBV-encoded RNA (EBER) in situ hybridization and constitutes about 8.7% of all GC, 3 ranging between 1.3% to 20.1% (or 2% to 18%). [4] [5] [6] Among EBV-associated neoplasms, EBVaGC is most common and distributed worldwide, while Burkitt's lymphoma and nasopharyngeal carcinoma are endemic to equatorial Africa and southeast China, respectively. Lymphoepithelioma-like carcinoma (LELC) is a relatively rare type of GC, which constitutes approximately 1% to 4% of all GCs and is highly associated with EBV infection. [7] [8] [9] The prevalence of EBVaGC among LELC of the stomach is over 90%, 3 and more than 80% of LELCs have been found to be EBV-associated. 10 It is now widely accepted that LELC of the stomach is associated with a significantly better prognosis. However, some studies have shown that EBVaGCs do not differ in the prognosis compared to their EBV-negative counterparts. [11] [12] [13] This discrepancy in prognosis may be associated with diverse pathologic features of EBVaGC. Conventional histologic types of GC other than LELC also are associated with EBV in about 10% to 20% of all GCs. 3, 14 In the current article, we reviewed the relationship between pathologic features, especially host cellular immune responses and prognosis in EBVaGC.
CLINICAL FEATURES OF EBV-ASSOCIATED GASTRIC CARCINOMA
The clinicopathologic features of EBVaGC observed in metaanalyses are described in Table 1 . Although some have demThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. onstrated that EBVaGC occur more frequently in male and in younger age group, most studies showed no evident age dependence of EBVaGC. 3, 6 In our Korean cohorts, although male affected more frequently than female patients, we failed to demonstrate any age preference. 11, 14 Moreover, although lymph node metastasis was significantly frequent in EBVaGCs compared to EBV-negative GCs, there was no significant difference in the depth of invasion or clinical stage between EBVaGC and EBV-negative GC. 6 Although the numbers of patients with pT3-4 stages were relatively smaller than control group, Song et al. 14 showed that EBVaGCs are associated with lower pT stages, pN stages and International Union Against Cancer/American Joint Committee on Cancer (UICC/AJCC) stages than control patients. Most studies did not show any relationship between EBV presence and GC prognosis. 15 Koriyama et al. 16 first demonstrated that EBV was related to poor prognosis in intestinaltype carcinoma, whereas the diffuse-type EBVaGC had better prognosis even when LELC were excluded. This study is the first demonstrating the relationship between prognosis and histologic type of EBVaGCs. In our analyses with large number of EBVaGCs, 14 although patients with EBVaGC showed longer overall and disease-free survival than patients with EBV-negative GC by univariate analysis, multivariate analysis with Cox proportional hazards failed to show any significant difference in spite of their lower UICC/AJCC stages. However, stratification of EBV-associated GCs by host cellular immune responses showed that patients with LELC and LELC+CLR have significantly longer overall survival time and disease-free survival (Table 2 ).
14 From a clinical perspective, endoscopy is the most useful modality for the diagnosis of EBVaGC. Although distinguishing endoscopic findings are not described, some have reported submucosal nodules of carcinoma with lymphoid stroma. 17, 18 In these circumstances, characteristic submucosal tumor-like protrusions without clear tumor margins are described. The submucosal mass lesion, one of the various appearances of LELC, can be misdiagnosed as submucosal tumors. 18 In these cases, endoscopic ultrasonography demonstrating hypoechoic submucosal mass (corresponding to lymphoid stroma composed of carcinoma cells and infiltrating lymphocytes) located in the hyperechoic submucosal layer of the gastric wall is useful distinguishing LELC from other submucosal tumors. 17, 19 The authors have experienced small numbers of LELC cases mimicking submucosal tumor on endoscopic and radiologic findings. In these Table 2 describes macroscopic and microscopic features of EBVaGC.
PATHOLOGIC FEATURES OF EBV-ASSOCIATED GASTRIC CARCINOMAS

Macroscopic fi ndings
EBVaGC develops most often in the proximal stomach, including cardia, fundus and body, in contrast to the predominance of antrum in EBV-negative GC in the GC prevalent areas such as Korea. EBVaGC was detected in 11.8% of the cases in the cardia, in 13.0% in the body, and in 5.9% in the antrum, indicating that there is a significant relationship between the tumor location in the stomach and EBVaGC. 6 Some have reported that macroscopic findings of advanced EBVaGC show markedly increased ratio of thickness to width compared to EBV-negative GC. [18] [19] [20] However, these observations were based on adopting only LELC and excluding other histologic types of EBVaGC. If a certain EBVaGC is conventionaltype adenocarcinoma rather than LELC, it can show conventional gross findings similar to EBV-negative counterparts.
There are scattered reports indicating that the incidence of multiple synchronous carcinomas appears to be higher in EBVaGC than in EBV-negative GC.
21,22
Microscopic fi ndings
EBVaGC can be divided into three histologic subtypes according to microscopic findings based on host cellular immune responses.
14 A recent study on 123 EBVaGCs showed that 53 (43.1%) was lymphoepithelioma-like carcinoma (LELC), 52 (42.3%) was Crohn's disease-like lymphocytic reaction (CLR), and 18 (14.6%) was conventional adenocarcinoma (CA). 14 
1) Lymphoepithelioma-like carcinoma
Typical microscopic findings of LELC are defined by 1) welldefined tumor margin, 2) dense lymphocytic infiltration of a degree whereby the number of tumor infiltrating lymphocytes was greater than the tumor cells throughout the tumor, 3) indistinct cytoplasmic borders and a syncytial growth pattern with poorly formed glandular structures, and 4) no desmoplasia (Fig. 1). 14 Particularly, in the intramucosal stage, LELC shows a 'lace pattern' which consists of the connection and fusion of neoplastic glands (Fig. 2) . 23 Although many EBVaGCs show the pathologic findings similar to LELC, diagnosis of EBVaGC need for caution because many lymphocytes can infiltrate around tumor cells in other subtypes of EBVaGC and confirmation of EBV is prerequisite. So, strict criteria to diagnose LELC should be applied in order to subclassify EBVaGC and further validate their clinical significances.
2) Carcinoma with Crohn's disease-like lymphoid reaction Carcinoma with Crohn's disease-like lymphoid reaction (CLR) was defined by 1) patchy lymphocytic infiltration with 3 or more lymphoid follicles with active germinal centers per tissue section at the advancing edge of the tumor, 2) smaller numbers of lymphocytes than tumor cells, 3) frequent tubule or gland formation, and 4) minimal or no desmoplasia (Fig. 3) . In this pathologic subtype, it is characteristic that desmoplastic reaction is less prominent than conventional-type adenocarcinoma, especially of diffuse-type.
3) Conventional-type adenocarcinoma Carcinomas other than LELC or CLR can be classified as conventional-type adenocarcinoma (CA). In contrast to extensive lymphocytic infiltrations found in LELC or CLR, CAs show scattered lymphocytes infiltration with prominent desmoplasia and rarely forms lymphoid follicles with prominent germinal centers (Fig. 4) . Sometimes, in the periphery of CAs, only 1 or 2 lymphoid aggregates per tissue section are observed. This subtype is least common among EBVaGCs and cannot be delineated histologically from EBV-negative counterparts without confirmation of EBV within tumor cells.
PROGNOSIS OF EBV-ASSOCIATED GASTRIC CARCINO-MA IN RELATION TO PATHOLOGY
Among the three histologic subtypes described earlier, patients with LELC subtype of EBVaGC show the best overall and disease-free survival followed by CLR, which showed better survival than CA patients.
14 So this histologic subclassification of EBVaGC into 3 distinct subsets seems to be a powerful prognostic parameter.
In patients with GC, tumor infiltrating lymphocytes or dendritic cells have been associated with favorable prognosis. [24] [25] [26] Several studies have reported that the infiltrating cells in EBVaGC are CD8+ T cells and mature dendritic cells. [27] [28] [29] Lymphocytic infiltration around tumor can be considered as a host immune reaction against tumor cells, although the exact cellular characteristics or their roles are not certain at the present time.
More dense lymphocytic infiltration could be considered as a stronger host immune reaction, and this assumption is well correlated with prognostic differences. Recent meta-analyses revealed that there was no significant association between EBVaGC and EBV-negative GC in the same tumor invasion depth (T stage) or lymph node metastasis (N stage). 6 Considering the prognostic significances of host cellular immune reaction, further studies are needed. Application of this type of histologic subclassification of EBVaGC, based mainly on host cellular immune response, may be helpful in predicting the prognosis of not only the patients with EBVaGC but also in the patients with other histological types of gastric cancer with negative EBV. Further elucidation of the underlying mechanisms of host cellular immune responses may guide the future development of immunotherapy as a therapeutic strategy for patients with GC.
CONCLUSION AND FUTURE PERSPECTIVES
EBV in situ hybridization is not routinely performed in daily pathology practice in many hospitals worldwide. Therefore, it is important to identify the characteristic pathological features of EBVaGC. Furthermore, pathologic subclassification of EBVaGCs according to histology reflecting host immune responses against tumor is an important prognostic factor. It will also be helpful to develop simple and easily applicable immunohistochemical methods to detect the EBV in the fixed tissue sections. Further research on underlying mechanisms of cellular immune reaction in EBVaGCs may play a key role in stimulating the innate immune response in patients with this highly aggressive carcinoma.
